Long-Term Effects of Peptide Use: Dose, Duration and IGF-1

How little long-term data exists

Most peptide discussions focus on the first few weeks of use. What years of use do hasn't been measured. The human studies behind the growth hormone (GH) peptides lifters use most, such as CJC-1295, ipamorelin and GHRP-2, lasted anywhere from a single dose to a few months.

FDA's December 2024 compounding advisory review of CJC-1295 said the safety data come from healthy adults who mostly got one to three doses, and that the long-term safety profile in humans "is unknown." Ipamorelin's published human data cover single IV doses and up to 7 days of IV use after abdominal surgery.

So this page works from indirect evidence: short peptide trials, a longer trial of a related GH secretagogue, and data on people with high GH and IGF-1 for years from acromegaly or prescription GH. For the dosing patterns themselves, see the overview of dosing protocols.

Desensitization: what human studies show

The most repeated long-term worry in forum guides is receptor desensitization: give the pituitary a constant signal and it stops responding. Human studies support a milder version of that idea than the guides suggest, and they contradict one common claim about CJC-1295.

CJC-1295 with DAC keeps GH pulses

CJC-1295 with DAC binds to albumin in the blood and lasts about a week (an estimated half-life of 5.8-8.1 days in a 2006 trial in healthy adults). Forum posts often say it makes GH "bleed" at a flat level with no pulses, blunting the body's own rhythm. The one study that measured this found otherwise. Ionescu and Frohman sampled blood every 20 minutes overnight in healthy men aged 20-40, before and one week after a single injection of 60 or 90 mcg/kg. GH pulses kept the same frequency and size. What changed was the level between pulses: trough GH rose about 7.5-fold, mean GH rose 46% and IGF-1 rose 45%.

That's one dose in a small group of young men, measured at one week, so it says nothing about months of repeated dosing. The real difference from short-acting Mod GRF 1-29 is that raised trough, which the body doesn't normally produce. Whether it matters over years is unknown.

An older study points the same way. In 1985, six healthy young men got a continuous 24-hour infusion of natural GHRH. Pulses continued and total GH output rose, but the GH response to an extra GHRH bolus at the end was less than half that of a control day (386 vs 877 mcg of GH). Constant GHRH didn't erase pulses; it did shrink the pituitary's reserve, at least within 24 hours.

GHRPs show partial, reversible attenuation

The ghrelin-mimicking peptides (GHRPs) have more data on repeated dosing. In a 1998 study, nine healthy young men injected 100 mcg of GHRP-2 under the skin once daily for 5 days. Peak GH fell from about 83 to 51 mcg/L between day 1 and day 5, and IGF-1 didn't rise. In a 16-week study of hexarelin, a close relative, given at 1.5 mcg/kg twice daily, the GH response to a test dose fell by about 45% by week 16. Four weeks after stopping, it was back to baseline. IGF-1 and body composition didn't change significantly.

A 1997 review of GHRPs described partial desensitization, stronger with continuous infusion and weaker with intermittent doses. That fits the forum idea that spaced doses and breaks help. It doesn't support the claim that heavy use makes the system "lazy" or permanently changes feedback loops; the one study that checked recovery saw it within a month. For how users structure on and off periods, see peptide cycling strategies.

IGF-1 and cancer risk

Much of what people want from GH secretagogues runs through insulin-like growth factor 1 (IGF-1), which the liver makes in response to GH. In the 2006 CJC-1295 trials, one injection raised IGF-1 1.5- to 3-fold for 9-11 days, and FDA's 2024 review noted IGF-1 above the normal range at the highest dose tested (250 mcg/kg).

The cancer concern comes from observational human data, not from peptide studies. A 2004 meta-analysis of 21 studies found that people with natural IGF-1 near the top of the normal range had modestly higher rates of prostate cancer and premenopausal breast cancer than people near the bottom (odds ratios about 1.5 and 1.65). The authors called the associations modest, and an association doesn't show that raising IGF-1 causes cancer.

Acromegaly, where a pituitary tumor drives high GH and IGF-1 for years, is the extreme case. A 2018 Danish cohort of 529 patients found overall cancer incidence only slightly above expected, and not significantly (standardized incidence ratio 1.1). In a meta-analysis of 23 studies including that one, the ratio was 1.5, higher for colorectal and thyroid cancer, though the authors saw signs of selection bias in smaller single-center studies. Prescription GH labeling also tells doctors to watch existing tumors for progression.

None of this shows what a few months of peptide-raised IGF-1 does to cancer risk. It does make IGF-1 held well above the age-adjusted range an unknown risk rather than a target. Reference ranges vary by age and lab assay, so the single "ideal" numbers passed around on forums mean different things for different people.

Glucose, fluid and other GH effects

The longest controlled trial of a GH secretagogue used MK-677 (ibutamoren), an oral ghrelin mimetic. It isn't a peptide, but it acts on the same receptor as ipamorelin and GHRP-2. In 65 healthy adults aged 60-81 taking 25 mg daily for up to two years, GH and IGF-1 rose to young-adult levels and fat-free mass rose 1.1 kg, against a small loss on placebo. Strength and function didn't improve. Fasting glucose went up by about 5 mg/dL and insulin sensitivity fell. Cortisol rose, and some participants had mild leg swelling. FDA's compounding safety list adds that an MK-677 trial in hip-fracture patients was stopped early for a possible heart-failure signal.

Prescription GH (somatropin) labeling lists similar effects in adults: fluid retention with swelling, joint pain and carpal tunnel symptoms, and reduced insulin sensitivity that can unmask diabetes. FDA's 2024 review said it had found no data suggesting CJC-1295 would avoid the risks on GH labels, and its safety notes add raised heart rate and a systemic vasodilatory reaction. FDA also described an unpublished Phase 2 trial in HIV lipodystrophy that was stopped after a participant had a fatal heart attack 2 hours after the 11th weekly dose; the treating physician blamed undiagnosed coronary artery disease. It's an anecdotal report, but one of the few accounts of CJC-1295 use beyond a few weeks. Our CJC-1295 profile covers its trial data in more detail.

GHRP-2 has an extra issue. In human studies, a single IV dose raised prolactin, ACTH and cortisol along with GH, and whether those rises persist with repeated use hasn't been studied well. Users also describe increased hunger and water retention; the GHRP-2 profile has more on these reports.

How users describe conservative and aggressive protocols

Forum and vendor guides often contrast two styles of long-term use. The doses below are what users and vendors describe, not tested regimens, and no trial has compared them.

The conservative pattern stays closer to the doses and durations that have been studied, and the GHRP studies suggest intermittent dosing desensitizes less. The aggressive pattern has a clearer path to IGF-1 above range and to the glucose changes seen with MK-677 and prescription GH. Neither has long-term human data, so the "10-year outlook" comparisons in some guides are guesses.

Users on peptide forums describe the trade-off in similar terms: stronger early effects from aggressive use, with more water retention and numb hands, then a fading response after a few months. These are self-reports involving products sold for research use, so actual doses and purity are uncertain.

Blood work users report tracking

Rising glucose and IGF-1 usually cause no symptoms, so lab tests are the only way to see them. Community writeups commonly describe testing:

• Before starting: IGF-1, fasting glucose and HbA1c, a lipid panel and a comprehensive metabolic panel
• Partway through a run (often 4-8 weeks in): IGF-1 and fasting glucose
• About 4 weeks after stopping: IGF-1, fasting glucose and HbA1c, to see whether values return to baseline

Prescription GH labeling calls for periodic glucose checks for the same reason. Because IGF-1 ranges differ between labs, results read with a clinician tend to be more useful than numbers compared on a forum.

What we still don't know

• Whether months or years of CJC-1295 with DAC, with its raised GH baseline, affect pituitary function after stopping. No study has looked.
• Whether the partial desensitization seen with GHRP-2 over 5 days and hexarelin over 16 weeks also happens with ipamorelin, which has no repeated-dose human studies by injection under the skin.
• How much peptide-raised IGF-1 changes cancer risk, if at all. Current evidence comes from natural IGF-1 levels and acromegaly, not from peptide users.
• How much of what users report reflects the peptides themselves rather than dose errors or product quality.